Mylan warned by FDA on testing failures

Mylan ($MYL) CEO Robert Coury (photo) was sent an FDA warning letter in mid-October as a result of a January-February 2011 inspection of a Puerto Rico plant. The letter, which was just posted to the FDA website, contains just two counts.

The first GMP violation involved pre-release confirmation that a manufactured product conformed to specs. The letter said the company lacked "appropriate laboratory determination" of conformance for each product batch.

For example, the letter said Mylan failed to complete a content uniformity test--a USP requirement--after loperamide hydrochloride capsules flunked conformance testing. In addition, in responding to the Form 483 observation about the test, Mylan failed to justify why it had not been completed.   

Mylan's second violation concerned its investigation of batch failures. The letter said that in several investigations, Mylan failed to provide supporting evidence of the causes it cited for out-of-specification results.

- here's Warning Letter 12-SJN-WL-01

Special Report: Fierce's 2011 warning letters report

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.